BAT-4706

N/A

Report date: 2023/11/24 16:03:18

Base Information

Drug NameBAT-4706

Drug Alias NameFc-glycosylated recombinant fully humanized anti-CTLA-4 monoclonal antibodyBAT-4706

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsCytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsSolid tumoursMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBio-Thera Solutions Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBio-Thera Solutions Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A